Equities research analysts expect TG Therapeutics Inc (NASDAQ:TGTX) to report earnings per share of ($0.43) for the current quarter, Zacks reports. Two analysts have made estimates for TG Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.48). TG Therapeutics posted earnings of ($0.59) per share during the same quarter last year, which indicates a positive year over year growth rate of 27.1%. The business is expected to report its next quarterly earnings report on Tuesday, August 6th.
According to Zacks, analysts expect that TG Therapeutics will report full-year earnings of ($1.58) per share for the current year, with EPS estimates ranging from ($1.83) to ($1.30). For the next financial year, analysts forecast that the firm will report earnings of ($1.29) per share, with EPS estimates ranging from ($1.61) to ($0.87). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover TG Therapeutics.
TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.01. TG Therapeutics had a negative net margin of 99,471.43% and a negative return on equity of 309.17%. The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million.
TGTX has been the topic of several research analyst reports. BidaskClub raised shares of TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, March 29th. Cantor Fitzgerald initiated coverage on shares of TG Therapeutics in a research report on Friday, March 29th. They issued an “overweight” rating and a $17.00 target price on the stock. Zacks Investment Research cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of TG Therapeutics in a research report on Friday, April 12th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $14.07.
Shares of TGTX traded up $0.14 during mid-day trading on Friday, hitting $7.26. The company had a trading volume of 1,070,953 shares, compared to its average volume of 1,373,582. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.72 and a quick ratio of 1.72. TG Therapeutics has a 1-year low of $3.32 and a 1-year high of $14.65.
A number of hedge funds and other institutional investors have recently bought and sold shares of TGTX. LPL Financial LLC purchased a new position in TG Therapeutics in the fourth quarter valued at approximately $49,000. NumerixS Investment Technologies Inc purchased a new position in TG Therapeutics in the fourth quarter valued at approximately $50,000. Ladenburg Thalmann Financial Services Inc. raised its holdings in TG Therapeutics by 46.5% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,927 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 2,200 shares during the period. National Asset Management Inc. purchased a new position in TG Therapeutics in the fourth quarter valued at approximately $58,000. Finally, Stifel Financial Corp purchased a new position in TG Therapeutics in the fourth quarter valued at approximately $59,000. Hedge funds and other institutional investors own 54.60% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Further Reading: What is a resistance level?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.